Treatment of Panic Disorder: Long Term Strategies
Panic Disorder, Agoraphobia
About this trial
This is an interventional treatment trial for Panic Disorder focused on measuring Adult, Cognitive Behavioral Therapy, Pharmacotherapy, Long term treatment, Remission and relapse, Male, Panic Disorder, Paroxetine, Serotonin Uptake Inhibitors, Panic Disorder -- *therapy, Panic Disorder -- drug therapy, Paroxetine -- *therapeutic use, Serotonin Uptake Inhibitors -- *therapeutic use
Eligibility Criteria
Inclusion Criteria: - primary diagnosis of Panic disorder with or without Agoraphobia (all levels of agoraphobia are included). Exclusion Criteria: current substance abuse or dependence, current active suicidal potential; any history of psychosis, bipolar disorder (I or II) or cyclothymia; pending application or existing medical disability claim; significant cognitive impairment, current uncontrolled general medical illness requiring intervention, psychotherapy directed at anxiety or panic which will not be discontinued by the first treatment visit, and daily use of 2mg of Xanax or equivalent. Exclusion criteria for paroxetine study: hypersensitivity to Selective Serotonin Reuptake Inhibitors (SSRI), pregnancy, lactation, or planned pregnancy during the course of the study, contemporaneous medication that may interfere or interact with paroxetine, prior treatment with therapeutic doses of paroxetine (40mg/d for 1 mo), concurrent treatment with antidepressants.
Sites / Locations
- Yale University, Department of Psychiatry, Anxiety Disorders Research Clinic
- Boston University, Department of Psychology, Center for Anxiety and Related Disorders
- Hillside Hospital Phobia Clinic
- University of Pittsburgh, Department of Psychiatry, Panic, Anxiety and Traumatic Grief Program